Diamond Biofund (TPE:6901) Other Current Receivables: NT$8.33 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6901 Diamond Biofund Inc TPE:6901
16 GF Score
Price NT$18.75
! 2 Warning Signs
View Full Analysis

What is Diamond Biofund Other Current Receivables?

Diamond Biofund TPE:6901 -9.64% 16 Other Current Receivables is NT$8.33 Mil as of Dec. 2025. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Diamond Biofund's Other Current Receivables for the quarter that ended in Dec. 2025 was NT$8.33 Mil.

Diamond Biofund's quarterly Other Current Receivables declined from Jun. 2025 (NT$8.23 Mil) to Sep. 2025 (NT$7.27 Mil) but then increased from Sep. 2025 (NT$7.27 Mil) to Dec. 2025 (NT$8.33 Mil).

Diamond Biofund's annual Other Current Receivables increased from Dec. 2023 (NT$2.64 Mil) to Dec. 2024 (NT$7.74 Mil) and increased from Dec. 2024 (NT$7.74 Mil) to Dec. 2025 (NT$8.33 Mil).

Diamond Biofund Other Current Receivables Related Terms

Diamond Biofund Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Diamond Biofund's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biofund Other Current Receivables Chart

Diamond Biofund Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 0.21 2.64 7.74 8.33

Diamond Biofund Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.74 14.74 8.23 7.27 8.33
TPE:6901
16GF Score
Diamond Biofund Inc TPE:6901
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biofund Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$8.33 Mil mean?
Diamond Biofund (TPE:6901) has a Other Current Receivables of NT$8.33 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Diamond Biofund and its competitors.
Is Diamond Biofund's Other Current Receivables too high?
Diamond Biofund's current Other Current Receivables is NT$8.33 Mil. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's Other Current Receivables compare to BLK and BX?
Diamond Biofund's Other Current Receivables of NT$8.33 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for an Asset Management company?
A good Other Current Receivables depends on the Asset Management industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Diamond Biofund and its competitors. Diamond Biofund's current Other Current Receivables is NT$8.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current Other Current Receivables of NT$8.33 Mil. The current Other Current Receivables is NT$8.33 Mil. Diamond Biofund's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current Other Current Receivables is NT$8.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diamond Biofund Business Description

Address Zhongxiao West Road, 34th Floor, No. 66, Section 1, Zhongzheng District, Taipei, TWN, 100
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score

Get the complete analysis for TPE:6901

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.75
Price